PubRank

Jette E Kristiansen

Author PubWeight™ 20.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003 1.30
2 Quinoline and cyanine dyes--putative anti-MRSA drugs. Int J Antimicrob Agents 2003 1.21
3 Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 2003 1.21
4 Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008 1.04
5 The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007 0.98
6 Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents 2007 0.93
7 Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo 2010 0.91
8 Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo 2005 0.87
9 Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. Int J Antimicrob Agents 2009 0.87
10 Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J Infect Chemother 2002 0.86
11 Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. Int J Antimicrob Agents 2003 0.84
12 Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int J Antimicrob Agents 2003 0.84
13 [Pigs as an infection source for methicillin resistant Staphylococcus aureus infections in humans]. Ugeskr Laeger 2008 0.84
14 "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006 0.81
15 A comparative analysis of in vitro and in vivo efficacies of the enantiomers of thioridazine and its racemate. PLoS One 2013 0.81
16 Effect of thioridazine stereoisomers on the drug accumulation of mouse lymphoma and human prostate cancer cell lines in vitro. In Vivo 2013 0.80
17 In vitro activity of phenothiazine derivatives in Enterococcus faecalis and Enterococcus faecium. Basic Clin Pharmacol Toxicol 2005 0.79
18 The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient. In Vivo 2005 0.78
19 Mycobacterium alsiense, a novel, slowly growing species isolated from two patients with pulmonary disease. J Clin Microbiol 2007 0.78
20 Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses". Recent Pat Antiinfect Drug Discov 2011 0.78
21 Nizatidine and omeprazole enhance the effect of metronidazole on Helicobacter pylori in vitro. Int J Antimicrob Agents 2002 0.77
22 Characterization of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semi-automated ethidium bromide method. In Vivo 2009 0.77
23 Prolonged exposure of methicillin-resistant Staphylococcus aureus (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. Int J Antimicrob Agents 2007 0.77
24 [The human in the art: Henrik Have's painting for a medical thesis]. Dan Medicinhist Arbog 2002 0.75
25 Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. Int J Antimicrob Agents 2013 0.75
26 [Letters from the Nobellaureter Paul Ehrlich to the Director for the State Serum Institute in Copenhagen, Thorvald Madsen]. Dan Medicinhist Arbog 2004 0.75